Belantamab Mafodotin Yields Good Response Rate in Patients With Relapsed, Refractory Multiple Myeloma
Among patients with relapsed/refractory multiple myeloma (RRMM), treatment with belantamab mafodotin appe...
Read moreResearch & Access Updates
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Isatuximab provides a clinically meaningful benefit in overall survival (OS) when added to pomalidomide a...
Read moreD-Rd Appears to Improve Long-Term Outcomes in Newly Diagnosed, Transplant-Ineligible Myeloma
Among patients with newly diagnosed, transplant-ineligible patients with multiple myeloma (MM), adding da...
Read moreCanadian myeloma research at 19th International Myeloma Society (IMS) Annual Meeting
The IMS Annual Meeting took place in Los Angeles from August 25-27, 2022. The meeting brought together in...
Read moreMyeloma Canada and IMD Health Announce Partnership to Improve Quality of Patient Education
IMD Health Global is pleased to announce an important new partnership with Myeloma Canada. This partnersh...
Read moreFDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma
The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic...
Read more